Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

EYA4 is inactivated biallelically at a high frequency in sporadic lung cancer and is associated with familial lung cancer risk.

Wilson IM, Vucic EA, Enfield KS, Thu KL, Zhang YA, Chari R, Lockwood WW, Radulovich N, Starczynowski DT, Banáth JP, Zhang M, Pusic A, Fuller M, Lonergan KM, Rowbotham D, Yee J, English JC, Buys TP, Selamat SA, Laird-Offringa IA, Liu P, Anderson M, You M, Tsao MS, Brown CJ, Bennewith KL, MacAulay CE, Karsan A, Gazdar AF, Lam S, Lam WL.

Oncogene. 2014 Sep 4;33(36):4464-73. doi: 10.1038/onc.2013.396. Epub 2013 Oct 7.

2.

Epigenetic mediated silencing of EYA4 contributes to tumorigenesis in oral dysplastic cells.

Towle R, Truong D, Garnis C.

Genes Chromosomes Cancer. 2016 Jul;55(7):568-76. doi: 10.1002/gcc.22360. Epub 2016 May 2.

PMID:
27015871
3.

Molecular genetics of small cell lung carcinoma.

Wistuba II, Gazdar AF, Minna JD.

Semin Oncol. 2001 Apr;28(2 Suppl 4):3-13. Review.

PMID:
11479891
5.
6.

Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers.

Imoto I, Izumi H, Yokoi S, Hosoda H, Shibata T, Hosoda F, Ohki M, Hirohashi S, Inazawa J.

Cancer Res. 2006 May 1;66(9):4617-26.

7.

Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.

Morrissey C, Martinez A, Zatyka M, Agathanggelou A, Honorio S, Astuti D, Morgan NV, Moch H, Richards FM, Kishida T, Yao M, Schraml P, Latif F, Maher ER.

Cancer Res. 2001 Oct 1;61(19):7277-81.

8.

EYA4 Acts as a New Tumor Suppressor Gene in Colorectal Cancer.

Kim SJ, Tae CH, Hong SN, Min BH, Chang DK, Rhee PL, Kim JJ, Kim HC, Kim DH, Kim YH.

Mol Carcinog. 2015 Dec;54(12):1748-57. doi: 10.1002/mc.22247. Epub 2015 Jan 25.

PMID:
25620232
9.

Quantitative analysis of mRNA expression levels and DNA methylation profiles of three neighboring genes: FUS1, NPRL2/G21 and RASSF1A in non-small cell lung cancer patients.

Pastuszak-Lewandoska D, Kordiak J, Migdalska-Sęk M, Czarnecka KH, Antczak A, Górski P, Nawrot E, Kiszałkiewicz JM, Domańska D, Brzeziańska-Lasota E.

Respir Res. 2015 Jun 26;16:76. doi: 10.1186/s12931-015-0230-6.

10.

Protocadherin 10 is frequently downregulated by promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer.

Tang X, Yin X, Xiang T, Li H, Li F, Chen L, Ren G.

Cancer Biomark. 2012-2013;12(1):11-9. doi: 10.3233/CBM-2012-00280.

PMID:
23321465
11.

Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours.

Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw JA, Hosoe S, Lerman MI, Minna JD, Maher ER, Latif F.

Oncogene. 2001 Mar 22;20(12):1509-18.

12.
13.

SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers.

Dallol A, Da Silva NF, Viacava P, Minna JD, Bieche I, Maher ER, Latif F.

Cancer Res. 2002 Oct 15;62(20):5874-80.

14.

CpG island methylator phenotype involving tumor suppressor genes located on chromosome 3p in non-small cell lung cancer.

Liu Z, Zhao J, Chen XF, Li W, Liu R, Lei Z, Liu X, Peng X, Xu K, Chen J, Liu H, Zhou QH, Zhang HT.

Lung Cancer. 2008 Oct;62(1):15-22. doi: 10.1016/j.lungcan.2008.02.005. Epub 2008 Mar 20.

PMID:
18358560
15.

Aberrant methylation of RASGRF2 and RASSF1A in human non-small cell lung cancer.

Chen H, Suzuki M, Nakamura Y, Ohira M, Ando S, Iida T, Nakajima T, Nakagawara A, Kimura H.

Oncol Rep. 2006 May;15(5):1281-5.

PMID:
16596198
16.

Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas.

Virmani AK, Rathi A, Sathyanarayana UG, Padar A, Huang CX, Cunnigham HT, Farinas AJ, Milchgrub S, Euhus DM, Gilcrease M, Herman J, Minna JD, Gazdar AF.

Clin Cancer Res. 2001 Jul;7(7):1998-2004.

17.

Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers.

Kaira K, Sunaga N, Tomizawa Y, Yanagitani N, Ishizuka T, Saito R, Nakajima T, Mori M.

Int J Oncol. 2007 Jul;31(1):169-73.

PMID:
17549418
18.

Frequent genetic and epigenetic abnormalities contribute to the deregulation of cytoglobin in non-small cell lung cancer.

Xinarianos G, McRonald FE, Risk JM, Bowers NL, Nikolaidis G, Field JK, Liloglou T.

Hum Mol Genet. 2006 Jul 1;15(13):2038-44. Epub 2006 May 12.

PMID:
16698880
19.

Epigenetic inactivation of the RUNX3 gene in lung cancer.

Sato K, Tomizawa Y, Iijima H, Saito R, Ishizuka T, Nakajima T, Mori M.

Oncol Rep. 2006 Jan;15(1):129-35.

PMID:
16328045

Supplemental Content

Support Center